Small Interfering RNA Market Outlook:
Small Interfering RNA Market size was valued at USD 20.62 billion in 2026 and is projected to reach USD 77.12 billion by the end of 2036, registering around 14.1% CAGR during the forecast period, i.e., 2027-2036. In 2027, the industry size of small interfering RNA is estimated at USD 23.53 billion.
The reason behind the growth is impelled by rising cases of cancer across the globe. Small interfering RNA has been studied as an effective treatment for cancer as it targets specific mRNA and blocks abnormal gene expression that causes the disease. By 2040, there will be more than 26 million new instances of cancer worldwide.
The growing partnerships and collaborations are believed to fuel the market growth. For instance, in 2022 Alnylam Pharmaceuticals and Novartis came together to treat liver disease by using siRNA to suppress a Novartis-discovered target, which could lead to the regeneration of functional liver cells and advance the possibility for new drugs in a variety of illness conditions.
Key Small Interfering RNA Market Insights Summary:
Regional Highlights:
- The North America small interfering RNA (SiRNA) market is anticipated to capture a 37% share by 2036, driven by increasing healthcare spending and academic R&D initiatives.
- The Asia Pacific market is projected to secure the second largest share by 2036, driven by biotechnology advancements in countries like India.
Segment Insights:
- The liposome based systemic therapy segment in the small interfering RNA market is expected to exhibit significant growth through 2036, driven by liposomes' efficiency in targeted drug delivery and immune response.
- The research institutions segment in the small interfering RNA market is projected to capture a 44% share by 2036, driven by siRNA’s gene-silencing potential and applications in research environments.
Key Growth Trends:
- Rising Popularity of Personalized Medicine
- Growing Geriatric Population
Major Challenges:
- High Cost of Developing SiRNA Therapies
- Stringent Regulations to Obtain Approvals for SiRNA Therapies
Key Players: GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis.
Global Small Interfering RNA Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2026 Market Size: USD 20.62 billion
- 2027 Market Size: USD 23.53 billion
- Projected Market Size: USD 77.12 billion by 2036
- Growth Forecasts: 14.1% CAGR (2027-2036)
Key Regional Dynamics:
- Largest Region: North America (37% Share by 2036)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, Germany, China, Japan, United Kingdom
- Emerging Countries: China, India, Japan, South Korea, Brazil
Last updated on : 31 August, 2026
Small Interfering RNA Market Growth Drivers and Challenges:
Growth Drivers
-
Rising Popularity of Personalized Medicine – Small interfering RNA (siRNA) has emerged as a promising possibility for precision therapy in cancer and other diseases as it is highly specific and can be easily generated for multiple target genes.
-
Growing Geriatric Population- The elderly population is more susceptible to several age-related diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease which may benefit from SiRNA treatment.According to estimates, the proportion of the world's population over 60 years old is anticipated to treble from roughly 11 to more than 22% by 2050.
Challenges
-
High Cost of Developing SiRNA Therapies - Despite their appealing method of action, small interfering RNA therapies confront several hurdles as they are often generated using chemical synthesis, which can be costly if large quantities are required.
-
Stringent Regulations to Obtain Approvals for SiRNA Therapies
- Development of Effective Delivery Methods Can be Challenging
Small Interfering RNA Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2026 |
|
Forecast Period |
2027-2036 |
|
CAGR |
14.1% |
|
Base Year Market Size (2026) |
USD 20.62 billion |
|
Forecast Year Market Size (2036) |
USD 77.12 billion |
|
Regional Scope |
|
Small Interfering RNA Market Segmentation:
Type Segment Analysis
The liposome based systemic therapy segment is estimated to account for 53% share of the global small interfering RNA market during the forecast period. Liposomes offer several advantages as a siRNA delivery system owing to their ability to improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Moreover, liposomes can selectively transport medications to the tumor, can be utilized to deliver specific medications to specific cell types to improve anti-tumor immune responses, and are known to be good carriers for drug delivery in conjunction with other therapies such as chemotherapy, radiation, and phototherapy.
Besides this, clinically proven liposomes are effective against pancreatic cancer as the only liposomal formulation currently licensed for the treatment of metastatic pancreatic cancer is nanoliposomal irinotecan (Onivyde) which was approved by the U.S. Food and Drug Administration (FDA) in 2022.
Indication Segment Analysis
SiRNA market from the oncology segment is set to garner a notable share of 39% shortly. SiRNA is one of the most essential therapeutic approaches for treating a variety of genetic disorders, including cancer since it has shown promise in the treatment of several malignancies, including breast and prostate cancer. To target cancer, siRNA can be supplied to the entire organism or to a specific tissue which will aid in reducing the expression of various multidrug-resistant genes in cancer cells.
End-User Segment Analysis
The research institutions segment is set to garner significant share of 44% during the forecast timeframe. SiRNA has recently been used in therapeutic applications and is now a potent method for studying gene function in research institutions that can be employed both in vitro and in vivo. Moreover, their use aids in the development of novel techniques to reduce off-target effects brought on by detrimental protein binding or unwanted targeting of mRNA in addition to assist researchers in better understanding the process of gene silence.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End-User |
|
|
Indication |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Small Interfering RNA Market Regional Analysis:
North American Market Insights
Small Interfering RNA market in North America is predicted to account for the largest share of 37% by 2036 impelled by the increasing spending in healthcare. This has led to the development of efficient and effective therapies for small interfering RNA in the region. Besides this, as a consequence, many academic institutions including Harvard University and the University of California, San Francisco (UCSF) have started researching small interfering RNA. For instance, at the UNIVERSITY OF CALIFORNIA, RIVERSIDE two scientists Shou-wei Ding and Shabihah Shahrudin identified in a recent research that a novel Dicer enzyme isoform a protein that functions similarly to another protein, protects mouse and for human stem cell treatment from RNA viruses which could significantly enhance siRNA therapeutics to treat SARS-CoV-2. According to estimates, in 2021, healthcare spending in the United States increased by more than 2% to roughly USD 4 trillion.
APAC Market Insights
The APAC Small Interfering RNA market is estimated to be the second largest, during the forecast timeframe led by growing advancements in biotechnology. In recent years, India's biotechnology industry has risen quickly owing to increased economic prosperity and health consciousness, which has led to significant progress in the development of siRNA therapies for the treatment of a variety of disease targets, including viral infections and cancer.
Small Interfering RNA Market Players:
- GE
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Scientific
- Arbutus Biopharma
- Sanofi Genzyme
- Sylentis
- Arrowhead Research
- Genecon Biotechnologies
- Silent Therapeutics
- Horizon Discovery
- OPKO Health
- Agios Pharmaceuticals, Inc.
- Novartis
Recent Developments
- Agios Pharmaceuticals, Inc. partnered with Alnylam Pharmaceuticals, Inc. announced to develop and commercialize Alnylam's innovative preclinical siRNA targeting TMPRSS6, for patients with polycythemia vera (PV), a rare hematologic condition. Furthermore, the company aims to provide a simple, disease-modifying therapy option that targets the underlying pathophysiology of PV and to provide a breakthrough therapy option for this patient community with significant unmet needs.
- Novartis received approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran) a small interfering RNA (siRNA) therapy a new strategy to lower low-density lipoprotein cholesterol also known as bad cholesterol in the bloodstream by increasing the liver's natural ability to suppress the creation of a protein that contributes to high circulating cholesterol levels to assist those who have difficulty sticking to self-administered medications with higher dose frequency.
- Report ID: 5297
- Published Date: Aug 31, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2027-2036
Copyright @ 2026 Research Nester. All Rights Reserved.
